Drug firm Glenmark said it has received approval from the US health regulator to market a generic medication to treat diabetes in the American market.
Glenmark Pharmaceuticals Inc, USA, a unit of the company, has received tentative approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets in strengths of 2.5 mg and 5 mg, the Mumbai-based drug maker said in a statement.
The company's product is the generic version of AstraZeneca AB's Onglyza tablets (2.5 mg and 5 mg), it added.
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza tablets (2.5 mg and 5 mg) achieved annual sales of around USD 122.3 million.
Glenmark said its current portfolio consists of 179 products authorised for distribution in the US marketplace.
The drug firm has 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.
How a drug company made $114 billion by gaming the US patent system
FDA acknowledges delays in response to US Infant formula shortage
Indian pharma sector set for 'volume to value leadership' journey in 2023
Zydus gets USFDA nod to market generic medicine for treating depression
Glenmark launches generic version of diuretic Bumetanide injection
Adani vs Hindenburg: SC to hear PILs, mull over setting up experts' panel
Godrej Properties acquires Raj Kapoor's Bungalow in Mumbai for Rs 500 cr
IndiGo plans flights to Nairobi, Jakarta, central Asian destinations: CEO
Tech giant Microsoft now supports Windows 11 on Apple's M1, M2 Macs
Twitter shuts two of three India offices; tells staff to work from home
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it stated.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)